Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Grants RNAi Patent License to Reagent Supplier Eurogentec

NEW YORK, July 12 (GenomeWeb News) - RNA interference company Alnylam Pharmaceuticals has given a non-exclusive license to patents in its Kreutzer-Limmer IP portfolio to Eurogentec, a life science reagent supplier.


The license enables Eurogentec to use the IP for research products and services, Alnylam said. The patent family covers short interfering RNAs and their use to mediate RNAi in mammalian cells.

The agreement brings to 11 the number of companies to which Alnylam has licensed the patent family. Six of these firms are research product suppliers, the company said.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.